---
title: "Ocrevus (ocrelizumab) in multiple sclerosis: Dosing and administration questions"
description: "Dosing and administration questions on Ocrevus (ocrelizumab) in multiple sclerosis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Administration and Dosing. Questions: What is the difference between Ocrevus and Ocrevus Zunovo? What is the Ocrevus IV dose and schedule? How long does an Ocrevus infusion take? Who can receive the 2-hour Ocrevus infusion? 7 further questions follow. 11 questions quoted from 7 sources."
canonical: "https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/dosing-and-administration"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ocrevus (ocrelizumab) in multiple sclerosis: Dosing and administration questions

Manufacturer: Genentech, Inc.  
Prescribing information: [Ocrevus](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf), [Ocrevus Zunovo](https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf)

Questions that apply to every indication of Ocrevus are on [Ocrevus (ocrelizumab), all indications](https://www.evicenter.com/medical-information/ocrevus).

## Administration

<a id="ocrevus-iv-vs-subcutaneous"></a>

### What is the difference between Ocrevus and Ocrevus Zunovo?

> “Ocrevus is administered as an intravenous infusion by a healthcare provider. The initial dose is two 300 mg infusions separated by 2 weeks, and subsequent doses are 600 mg every 6 months, with infusion times ranging between 2 to 3.5 hours.”

Source: [OCREVUS: RMS and PPMS Treatment, captured 2026-11-12](https://www.ocrevus-hcp.com/#:~:text=Ocrevus%20is%20administered%20as%20an,between%202%20to%203.5%20hours.)

> “Ocrevus Zunovo is administered in the abdomen subcutaneously by a healthcare provider. The initial dose is a single 920 mg injection with 23,000 units of hyaluronidase. Subsequent doses consist of a 920 mg injection with 23,000 units of hyaluronidase administered every 6 months. The injection typically lasts about 10 minutes.”

Source: [OCREVUS: RMS and PPMS Treatment, captured 2026-11-12](https://www.ocrevus-hcp.com/#:~:text=Ocrevus%20Zunovo%20is%20administered%20in,typically%20lasts%20about%2010%20minutes.)

> “OCREVUS ZUNOVO has different dosage and administration instructions than intravenous ocrelizumab”

Source: [OCREVUS: Access, captured 2026-11-12](https://www.ocrevus-hcp.com/access/incorporating-ocrevus.html#:~:text=OCREVUS%20ZUNOVO%20has%20different%20dosage%20and%20administration%20instructions%20than%20intravenous%20ocrelizumab)

> “*Does not include all aspects of treatment. Actual injection time may vary.”

Source: [OCREVUS: Access, captured 2026-11-12](https://www.ocrevus-hcp.com/access/incorporating-ocrevus.html#:~:text=%2ADoes%20not%20include%20all%20aspects%20of%20treatment.%20Actual%20injection%20time%20may%20vary.)

<a id="ocrevus-iv-infusion-time"></a>

### How long does an Ocrevus infusion take?

Applies to: Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS intravenous)

> “Initial dose (600 mg) administered as 2 infusions<sup>2</sup>
> Infusion 1
>
> Day 1
> 300 mg in 250 mL
>
> 2.5 hour infusion: Start at a rate of 30 mL/hr. Thereafter, increase the rate by 30 mL/hr every 30 minutes to a maximum of 180 mL/hr. Each infusion will last 2.5 hours or longer.*
>
> Infusion 2
>
> Day 15
> 300 mg in 250 mL”

Source: [OCREVUS: Dosing and Administration, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/dosing-administration.html#:~:text=Initial%20dose%20%28600%20mg%29%20administered,300%20mg%20in%20250%20mL)

> “Subsequent 
> Doses 
> (one infusion) 
> every 6 
> months)<sup>2</sup> 
>
> Option 1 
>
> Infusion of 
> approximately 
> 3.5 hours 
> duration<sup>3</sup> 
>
> 600 mg 
> in 500 mL 
> • Start at 40 mL per hour 
> • Increase by 40 mL per hour every 30 
> minutes 
> • Maximum: 200 mL per hour 
> • Duration: 3.5 hours or longer 
> OR 
> Option 2 
> (If no prior 
> serious 
> infusion 
> reaction with 
> any previous 
> OCREVUS 
> infusion)<sup>4</sup>  
>
> Infusion of 
> approximately 
> 2 hours 
> duration<sup>3</sup> 
> 600 mg 
> in 500 mL 
> • Start at 100 mL per hour for the first 
> 15 minutes 
> • Increase to 200 mL per hour for the 
> next 15 minutes 
> • Increase to 250 mL per hour for the 
> next 30 minutes 
> • Increase to 300 mL per hour for the 
> remaining 60 minutes 
> • Duration: 2 hours or longer”

Source: [OCREVUS: OCREVUS \[IV\], page 5, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=5)

> “*Infusion time may take longer if the infusion is interrupted or slowed. No change in premedication, dose, formulation, or post-treatment monitoring between infusion timing options.”

Source: [OCREVUS: Dosing and Administration, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/dosing-administration.html#:~:text=%2AInfusion%20time%20may%20take%20longer,monitoring%20between%20infusion%20timing%20options.)

Note: The subsequent-dose passage is from Table 1 of the OCREVUS Prescribing Information.

<a id="ocrevus-two-hour-infusion-eligibility"></a>

### Who can receive the 2-hour Ocrevus infusion?

Applies to: Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS intravenous)

> “2-hour infusion is available for patients who have not experienced serious IRs with any previous OCREVUS infusion.”

Source: [OCREVUS: Dosing and Administration, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/dosing-administration.html#:~:text=2%2Dhour%20infusion%20is%20available%20for,with%20any%20previous%20OCREVUS%20infusion.)

> “*Infusion time may take longer if the infusion is interrupted or slowed. No change in premedication, dose, formulation, or post-treatment monitoring between infusion timing options.”

Source: [OCREVUS: Dosing and Administration, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/dosing-administration.html#:~:text=%2AInfusion%20time%20may%20take%20longer,monitoring%20between%20infusion%20timing%20options.)

<a id="ocrevus-two-hour-infusion-ensemble-plus"></a>

### Is the 2-hour Ocrevus infusion as safe as the standard 3.5-hour infusion (ENSEMBLE PLUS)?

Applies to: Adults with relapsing-remitting multiple sclerosis receiving 2-hour OCREVUS infusions (ENSEMBLE PLUS substudy)

> “The safety of the 2-hour OCREVUS infusion was evaluated in Study 4 (NCT03085810), a prospective, 
> multicenter, randomized, double-blind, controlled, parallel arm substudy in adult patients with Relapsing-
> Remitting Multiple Sclerosis who were naïve to other non-steroid therapies for MS and did not experience a 
> serious infusion reaction with any previous OCREVUS infusion.”

Source: [OCREVUS: OCREVUS \[IV\], page 22, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=22)

> “The primary endpoint of the substudy was the proportion of patients with infusion reactions occurring during or 
> within 24 hours following the first randomized infusion of OCREVUS.”

Source: [OCREVUS: OCREVUS \[IV\], page 23, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=23)

> “The primary analysis was performed 
> when 580 patients were randomized, at which time 469/579 (81%) of the treated patients had received only a 
> single randomized infusion of OCREVUS.”

Source: [OCREVUS: OCREVUS \[IV\], page 23, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=23)

> “24.4%
>
> 2-hour infusion
>
> 23.3%
>
> 3.5- to 4-hour infusion”

Source: [OCREVUS: Dosing and Administration, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/dosing-administration.html#:~:text=24.4%25,3.5%2D%20to%204%2Dhour%20infusion)

This passage is in a collapsed section of the page; select: ENSEMBLE PLUS STUDY

> “The proportions of patients with infusion reactions occurring during 
> or within 24 hours following the first randomized infusion in this substudy were similar between the 2-hour and 
> 3.5-hour infusion groups (24.4% versus 23.3%, respectively). Overall, in all randomized doses, 27.1% of the 
> patients in the 2-hour infusion group and 25.0% of the patients in the 3.5-hour infusion group reported mild or 
> moderate infusion reactions; two infusion reactions were severe in intensity, with one severe infusion reaction 
> (0.3%) reported in one patient in each group in this substudy [see Warnings and Precautions (5.1)]. There were 
> no life-threatening, fatal, or serious infusion reactions in this substudy.”

Source: [OCREVUS: OCREVUS \[IV\], page 23, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=23)

Note: The dosing page reports the ENSEMBLE PLUS substudy with the same infusion reaction rates (24.4% and 23.3%) that the Prescribing Information reports for Study 4.

<a id="ocrevus-zunovo-injection"></a>

### How is Ocrevus Zunovo injected?

Applies to: Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS ZUNOVO subcutaneous)

> “OCREVUS ZUNOVO should be administered via subcutaneous injection by a healthcare professional. Do not administer OCREVUS ZUNOVO intravenously<sup>1</sup>”

Source: [OCREVUS: Dosing, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo/dosing-administration.html#:~:text=OCREVUS%20ZUNOVO%20should%20be%20administered,Do%20not%20administer%20OCREVUS%20ZUNOVO)

> “Administer 23 mL of OCREVUS ZUNOVO subcutaneously in the abdomen for approximately 10 minutes. DO NOT administer the remaining priming volume in the SC infusion set to the patient<sup>1,2</sup>”

Source: [OCREVUS: Dosing, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo/dosing-administration.html#:~:text=Administer%2023%20mL%20of%20OCREVUS,SC%20infusion%20set%20to%20the)

> “The recommended injection site should be the abdomen, except for 2 inches (5 cm) around the navel<sup>1</sup>”

Source: [OCREVUS: Dosing, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo/dosing-administration.html#:~:text=The%20recommended%20injection%20site%20should,inches%20%285%20cm%29%20around%20the)

> “OCREVUS ZUNOVO injections should not be administered into areas where the skin is red, bruised, tender, or hard or areas where there are moles or scars<sup>1</sup>”

Source: [OCREVUS: Dosing, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo/dosing-administration.html#:~:text=OCREVUS%20ZUNOVO%20injections%20should%20not,where%20there%20are%20moles%20or)

> “OCREVUS ZUNOVO can be administered with a syringe pump in lieu of manual injection<sup>1</sup>”

Source: [OCREVUS: Dosing, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo/dosing-administration.html#:~:text=OCREVUS%20ZUNOVO%20can%20be%20administered,pump%20in%20lieu%20of%20manual)

<a id="ocrevus-zunovo-self-injection"></a>

### Can Ocrevus Zunovo be self-injected?

Applies to: Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS ZUNOVO subcutaneous)

> “OCREVUS ZUNOVO should be administered via subcutaneous injection by a healthcare professional. Do not administer OCREVUS ZUNOVO intravenously<sup>1</sup>”

Source: [OCREVUS: Dosing, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo/dosing-administration.html#:~:text=OCREVUS%20ZUNOVO%20should%20be%20administered,Do%20not%20administer%20OCREVUS%20ZUNOVO)

<a id="ocrevus-zunovo-where-given"></a>

### Can Ocrevus Zunovo be given in clinics without IV infusion capabilities?

Applies to: Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS ZUNOVO subcutaneous)

> “OCREVUS ZUNOVO may be administered in multiple sites of treatment, including clinics without IV infusion capabilities<sup>1</sup>”

Source: [OCREVUS: Dosing, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo/dosing-administration.html#:~:text=OCREVUS%20ZUNOVO%20may%20be%20administered,including%20clinics%20without%20IV%20infusion)

> “Identify qualified medical personnel at the office to perform the injection; they must be able to administer a complex biologic like OCREVUS ZUNOVO”

Source: [OCREVUS: Access, captured 2026-11-12](https://www.ocrevus-hcp.com/access/incorporating-ocrevus.html#:~:text=Identify%20qualified%20medical%20personnel%20at,complex%20biologic%20like%20OCREVUS%20ZUNOVO)

> “Ensure relevant staff are trained on appropriate subcutaneous administration of OCREVUS ZUNOVO”

Source: [OCREVUS: Access, captured 2026-11-12](https://www.ocrevus-hcp.com/access/incorporating-ocrevus.html#:~:text=Ensure%20relevant%20staff%20are%20trained%20on%20appropriate%20subcutaneous%20administration%20of%20OCREVUS%20ZUNOVO)

<a id="ocrevus-premedication"></a>

### What premedication is needed before Ocrevus or Ocrevus Zunovo?

> “For OCREVUS ZUNOVO, administer oral pre-medication (e.g., dexamethasone or an equivalent corticosteroid, and an antihistamine) at least 30 minutes prior to each OCREVUS ZUNOVO injection to reduce the risk of injection reactions. The addition of an antipyretic (e.g., acetaminophen) may also be considered.
>
> For OCREVUS, administer pre-medication (e.g., methylprednisolone or an equivalent corticosteroid, and an antihistamine) to reduce the frequency and severity of infusion reactions. The addition of an antipyretic (e.g., acetaminophen) may also be considered.”

Source: [OCREVUS: Important Safety Information for HCPs, captured 2026-11-12](https://www.ocrevus-hcp.com/safety.html#:~:text=For%20OCREVUS%20ZUNOVO%2C%20administer%20oral,addition%20of%20an%20antipyretic%20%28e.g.%2C%20acetaminophen%29%20may%20also%20be%20considered.)

> “Premedicate with methylprednisolone (or an equivalent corticosteroid) administered intravenously approximately 30 minutes prior to each OCREVUS infusion to reduce the frequency and severity of infusion reactions<sup>2</sup>”

Source: [OCREVUS: Dosing and Administration, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/dosing-administration.html#:~:text=Premedicate%20with%20methylprednisolone%20%28or%20an,frequency%20and%20severity%20of%20infusion)

On the page, select: ADMINISTER PREMEDICATION

> “Premedicate with an antihistamine (eg, diphenhydramine) approximately 30 to 60 minutes prior to each OCREVUS infusion to further reduce the frequency and severity of infusion reactions. The addition of an antipyretic (eg, acetaminophen) may also be considered<sup>2</sup>”

Source: [OCREVUS: Dosing and Administration, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/dosing-administration.html#:~:text=Premedicate%20with%20an%20antihistamine%20%28eg%2C,%28eg%2C%20acetaminophen%29%20may%20also%20be)

On the page, select: ADMINISTER PREMEDICATION

> “Although patients must take the same types of premedications as they do for OCREVUS [IV], the premedications for OCREVUS ZUNOVO are administered orally.
>
> Administer at least 30 minutes prior to each OCREVUS ZUNOVO administration
> 20 mg dexamethasone (or equivalent corticosteroid)
> An antihistamine (e.g., desloratadine)
> The addition of an antipyretic (e.g., acetaminophen) may also be considered
>
> Oral premedications can be taken at home or in office, subject to the prescribing physician’s discretion. Consider how the patient has been instructed to take the premedications by their prescriber prior to the scheduled visit.”

Source: [OCREVUS: Access, captured 2026-11-12](https://www.ocrevus-hcp.com/access/incorporating-ocrevus.html#:~:text=Although%20patients%20must%20take%20the,prior%20to%20the%20scheduled%20visit.)

## Dosing

<a id="ocrevus-iv-dosing-schedule"></a>

### What is the Ocrevus IV dose and schedule?

Applies to: Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS intravenous)

> “OCREVUS is administered as an intravenous infusion. The initial dose is split into two equal infusions 
> administered two weeks apart. Subsequent doses are administered every 6 months thereafter (see Table 1).”

Source: [OCREVUS: OCREVUS \[IV\], page 4, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=4)

> “The first dose of OCREVUS is split between 2 treatments, for a total of 3 treatments in the first year<sup>2</sup>”

Source: [OCREVUS: Dosing and Administration, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/dosing-administration.html#:~:text=The%20first%20dose%20of%20OCREVUS,3%20treatments%20in%20the%20first)

> “<sup>2</sup> Administer the first Subsequent Dose 6 months after Infusion 1 of the Initial Dose.”

Source: [OCREVUS: OCREVUS \[IV\], page 5, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=5)

> “Ocrevus is administered as an intravenous infusion by a healthcare provider. The initial dose is two 300 mg infusions separated by 2 weeks, and subsequent doses are 600 mg every 6 months, with infusion times ranging between 2 to 3.5 hours.”

Source: [OCREVUS: RMS and PPMS Treatment, captured 2026-11-12](https://www.ocrevus-hcp.com/#:~:text=Ocrevus%20is%20administered%20as%20an,between%202%20to%203.5%20hours.)

<a id="ocrevus-zunovo-dosing"></a>

### What is the Ocrevus Zunovo dose?

Applies to: Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS ZUNOVO subcutaneous)

> “The recommended dosage of OCREVUS ZUNOVO is 920 mg/23,000 units (920 mg ocrelizumab and 23,000 
> units of hyaluronidase) administered as a single 23 mL subcutaneous injection in the abdomen over approximately 
> 10 minutes every 6 months.”

Source: [OCREVUS: OCREVUS ZUNOVO, page 4, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf#page=4)

<a id="ocrevus-missed-dose"></a>

### What if an Ocrevus or Ocrevus Zunovo dose is missed?

> “If a planned infusion of OCREVUS is missed, administer it as soon as possible; do not wait until the next scheduled dose. Reset the dose schedule to administer the next sequential dose 6 months after the missed dose is administered.”

Source: [OCREVUS: Dosing and Administration, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/dosing-administration.html#:~:text=If%20a%20planned%20infusion%20of,the%20missed%20dose%20is%20administered.)

> “Doses of OCREVUS must be separated by at least 5 months [see Dosage and 
> Administration (2.3)].”

Source: [OCREVUS: OCREVUS \[IV\], page 6, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=6)

> “If a planned injection of OCREVUS ZUNOVO is missed, administer it as soon as possible; do not wait until the next scheduled dose. Reset the dose schedule to administer the next sequential dose 6 months after the missed dose is administered. Doses of OCREVUS ZUNOVO must be separated by at least 5 months.”

Source: [OCREVUS: Dosing, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo/dosing-administration.html#:~:text=If%20a%20planned%20injection%20of,by%20at%20least%205%20months.)

## Related pages
- [Medical information: Ocrevus (ocrelizumab): Multiple sclerosis](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis)
- [Indication](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/drug-interactions)
- [Storage and supply](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/storage-and-supply)
